PCT

WORLD INTELLECTUAL PROPERTY ORGANIZATION
International Bureau

INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(51) International Patent Classification 7 :
A61K 9/16, A61P 35/00

A1

(11) International Publication Number: WO 00/41678

(43) International Publication Date: 20 July 2000 (20.07.00)

(21) International Application Number: PCT/US99/30814

(22) International Filing Date: 23 December 1999 (23.12.99)

(30) Priority Data:
09/227,852 11 January 1999 (11.01.99) US

(71) Applicant *(for all designated States except US)*: GUILFORD PHARMACEUTICALS INC. [US/US]; 6611 Tributary Street, Baltimore, MD 21224 (US).

(72) Inventor; and
(75) Inventor/Applicant *(for US only)*: DANG, Wenbin [CN/US]; 3304 Governor Howard Drive, Ellicott City, MD 21043 (US).

(74) Agent: KULIK, David, J.; Howrey, Simon, Arnold & White LLP, 1299 Pennsylvania Avenue, N.W., Box 34, Washington, DC 20004–2402 (US).

(81) Designated States: AE, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CR, CU, CZ, DE, DK, DM, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW, ARIPO patent (GH, GM, KE, LS, MW, SD, SL, SZ, TZ, UG, ZW), Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European patent (AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG).

Published
With international search report.

(54) Title: METHODS FOR TREATING OVARIAN CANCER, POLY(PHOSPHOESTER) COMPOSITIONS, AND BIODEGRADABLE ARTICLES FOR SAME

(57) Abstract

Biodegradable polymer compositions suitable for intraperitoneal administration to treat a mammalian subject having ovarian cancer are described. The composition comprising: (a) at least one antineoplastic agent and (b) a biodegradable phosphoester polymer wherein the polymer composition provides extended release of the antineoplastic agent into the peritoneum of the subject; wherein the polymer composition increases the median survival rate from the cancer by at least about 10%, as compared with the median survival rate obtained by administration of a composition comprising the same dosage of the antineoplastic agent without the biodegradable polymer. Solid articles and methods for treating ovarian cancer are also described.